Eisai Co., Ltd.｜A human health care company

Eisai Releases Corporate Film “1 Percent, 1 Mission. Change the World.”

Learn more

Eisai Releases Corporate Film “1 Percent, 1 Mission. Change the World.”

Learn more
Human Capital Report 2024

Learn more

Human Capital Report 2024

Learn more
Value Creation Report 2024

Learn more

Value Creation Report 2024

Learn more

July 23, 2025

Launch of Beova® Tablets in Thailand for Overactive Bladder
July 22, 2025

Eisai To Present Four-Year Efficacy And Safety Data On Continuous Treatment With Lecanemab At The Alzheimer’s Association International Conference 2025
Latest findings from Eisai's robust Alzheimer's disease (AD) pipeline include results from lecanemab long-term data, an immunoassay for measuring amyloid-β protofibrils in cerebrospinal fluid, and a subcutaneousl form of lecanemab for continued treatment of AD
AD is a progressive, relentless disease caused by a continuous underlying neurotoxic process that begins before and continues after plaque deposition
July 16, 2025

Eisai Awarded “The 9th Bioindustry Award”
for Drug Discovery Research for Anti- Amyloid β Monoclonal Antibody Lecanemab
July 14, 2025

“URECE®” (Dotinurad) Launched in China as a treatment for Gout
July 9, 2025

Update on the Cost-Effectiveness Evaluation of LEQEMBI® by the Central Social Insurance Medical Council of Japan’s Ministry of Health, Labour and Welfare

February 19, 2025

Eisai’s Corporate Pension Fund Announces Adoption of “Asset Owner Principles”
October 3, 2024

EISAI NAMED AS ONE OF NEWSWEEK’S WORLD’S MOST TRUSTWORTHY COMPANIES 2024
June 21, 2024

Notification Regarding Revision of “Eisai Global Code of Conduct for Business Partners”
June 3, 2024

The Naito Museum of Pharmaceutical Science and Industry Listed as “Registered Museum”
April 8, 2024

Eisai Participates in Kakamigahara City’s SDGs Promotion Program through its Activities Including Waste Recycling at the Kawashima Plant

Eisai at a Glance

Eisai Group Worldwide

Eisai's hhc Concept

Innovation

About Eisai

Investors

Sustainability

Sustainability

Making our medicines available to those who need them

32 countries 2.53billion tablets

Number of countries supplied with lymphatic filariasis treatment
and volume supplied (as of June 2025)

Eisai is promoting initiatives for improving access to medicines to contribute to people in developing and emerging countries

Sustainability TOP